[{"id":"fd42013f-b184-4a94-989c-04a171110182","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214886","created_at":"2021-01-18T20:31:24.535Z","updated_at":"2024-07-02T16:36:05.519Z","phase":"Phase 1","brief_title":"CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04214886","lead_sponsor":"Loyola University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19-CD34 CAR transduced T cells • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/11/2022","primary_completion_date":" 08/11/2022","study_txt":" Completion: 12/31/2034","study_completion_date":" 12/31/2034","last_update_posted":"2022-08-15"}]